NTLA Q2 2022 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+114.2% YoY

Gross Profit

-$76M-542.9% margin

Operating Income

-$98M-700.6% margin

Net Income

-$101M-717.6% margin

EPS (Diluted)

$-1.33

QoQ Revenue Growth

+24.7%

Cash Flow

Operating Cash Flow

-$85M

Free Cash Flow

-$89M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$230M

Stockholders' Equity

$881M

Cash & Equivalents

$148M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$7M	+114.2%
Gross Profit	-$76M	-$52M	-45.5%
Operating Income	-$98M	-$69M	-42.4%
Net Income	-$101M	-$69M	-46.3%